---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021198"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:53:40.849725+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eledon reports Q1 net loss $10.8M; clinical and financing updates on tegoprubart

## Summary
- Net loss of $10.8M ($0.75/share) vs $9.9M ($0.69) in Q1 2022; R&D expenses rose to $8.1M.
- Cash $46.5M at March 31; second-quarter financing provided $35M upfront (up to $185M) to fund Phase 2 BESTOW.
- Phase 1b kidney transplant data (3 patients): no acute rejection; mean eGFR >70 mL/min/1.73m2 at timepoints up to 31 weeks.
- Phase 2a IgAN study: tegoprubart safe and well tolerated; no serious/severe AEs; 4 patients completed ≥24 weeks.
- Phase 2 BESTOW trial expected to initiate mid-2023; updated Phase 1b data anticipated late 2023.

## SEC filing metadata
- accession: 0000950170-23-021198
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017023021198/0000950170-23-021198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017023021198/eldn-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021198
- JSON: https://secwatch.observer/filing/0000950170-23-021198.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021198.txt

## Key facts
- Earnings Releases
  Eledon Pharmaceuticals, Inc. reported three months ended March 31, 2023 results: net income net loss of $10.8 million, or $0.75 per share, EPS $0.75 per share.
  - Period: three months ended March 31, 2023
  - Net income: net loss of $10.8 million, or $0.75 per share
  - EPS: $0.75 per share
  - Result: reported results
  source text: The Company reported a net loss of $10.8 million, or $0.75 per share, for the three months ended March 31, 2023, compared to a net loss of $9.9 million, or $0.69 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404281/000095017023021198/0000950170-23-021198-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.